Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | KDM6B | O15054 | 1/20 | 0.35 |
| ▸ | KDM5C | P41229 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.35 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL348034 | 1.00 | HTT (1.00) | HTTMGAMGAASIMGAM2 | |
| SCHEMBL3389582 | 1.00 | HTT (1.00) | HTTMGAMGAASIMGAM2 | |
| SCHEMBL348035 | 1.00 | HTT (1.00) | HTTMGAMGAASIMGAM2 | |
| SCHEMBL7746127 | 0.97 | HTT (0.94) | HTTMGAMGAASIMGAM2 | |
| SCHEMBL348060 | 0.87 | HTT (0.76) | HTTMGAMGAASIMGAM2 | |
| SCHEMBL346894 | 0.87 | HTT (0.76) | HTTMGAMGAASIMGAM2 | |
| SCHEMBL346893 | 0.87 | HTT (0.76) | HTTMGAMGAASIMGAM2 | |
| SCHEMBL9959054 | 0.87 | HTT (0.76) | HTTMGAMGAASIMGAM2 | |
| SCHEMBL16627957 | 0.87 | HTT (0.76) | HTTMGAMGAASIMGAM2 | |
| SCHEMBL348061 | 0.87 | HTT (0.76) | HTTMGAMGAASIMGAM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220127293-A1 | LIQUID METAL COMPLEX HAVING OXYGEN-ABSORBING ABILITY | SHARP KABUSHIKI KAISHA (JP) | 2022-04-28 | — | — | US | claimed |
| US-7896935-B2 | Process of conducting reactions or separation in a microchannel with internal fin support for catalyst or sorption medium | VELOCYS, INC. (US) | 2011-03-01 | — | — | US | claimed |
| EP-2210268-A1 | NOVEL CHEMISTRY USED IN BIOSENSORS | Ohmx Corporation (US) | 2010-07-28 | — | — | EP | claimed |
| WO-2009052436-A1 | NOVEL CHEMISTRY USED IN BIOSENSORS | OHMX CORPORATION (US) | 2009-04-23 | — | — | WO | claimed |
| JP-2007534457-A | — | — | 2007-11-29 | — | — | JP | claimed |
| US-20070140955-A1 | MICROCHANNEL WITH INTERNAL FIN SUPPORT FOR CATALYST OR SORPTION MEDIUM | TONKOVICH ANNA L | 2007-06-21 | — | — | US | claimed |
| US-7220390-B2 | Microchannel with internal fin support for catalyst or sorption medium | VELOCYS, INC. (US) | 2007-05-22 | — | — | US | claimed |
| EP-1631376-A1 | MICROCHANNEL WITH INTERNAL FIN SUPPORT FOR CATALYST OR SUPPORT MEDIUM | Velocys, Inc. (US) | 2006-03-08 | — | — | EP | claimed |
| EP-1562688-A1 | PROCESS FOR SEPARATING A FLUID COMPONENT FROM A FLUID MIXTURE BY SORPTION USING MICROCHANNEL PROCESS TECHNOLOGY | Velocys, Inc. (US) | 2005-08-17 | — | — | EP | claimed |
| WO-2004103550-A1 | MICROCHANNEL WITH INTERNAL FIN SUPPORT FOR CATALYST OR SUPPORT MEDIUM | VELOCYS INC. (US) | 2004-12-02 | — | — | WO | claimed |
| US-20040228781-A1 | chemical reactors having microstructure passageways, catalysts supports, absorber materials and heat exchangers | VELOCYS, INC. | 2004-11-18 | — | — | US | claimed |
| WO-2004041414-A1 | PROCESS FOR SEPARATING A FLUID COMPONENT FROM A FLUID MIXTURE BY SORPTION USING MICROCHANNEL PROCESS TECHNOLOGY | VELOCYS, INC. (US) | 2004-05-21 | — | — | WO | claimed |
| US-6652627-B1 | Process for separating a fluid component from a fluid mixture using microchannel process technology | VELOCYS, INC. | 2003-11-25 | — | — | US | claimed |
| CN-115605479-B | Pyridopyrimidine derivatives, preparation method thereof and application thereof in medicines | 江苏恒瑞医药股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20230422602-A1 | CERIUM-ETHYLENEDIAMINE KETONE-TYPE AND CERIUM-SALEN-TYPE COMPLEXES AND USE THEREOF IN ORGANIC ELECTRONICS | Credoxys GmbH (DE) | 2023-12-28 | — | — | US | disclosed |
| EP-4244910-A1 | CERIUM-ETHYLENEDIAMINE KETONE-TYPE AND CERIUM-SALEN-TYPE COMPLEXES AND USE THEREOF IN ORGANIC ELECTRONICS | Credoxys GmbH c/o Institut for Applied Physics (DE) | 2023-09-20 | — | — | EP | disclosed |
| EP-0249614-A1 | OLIGOMERIZATION PROCESS. | COMMW SCIENT IND RES ORG (AU) | 1987-12-23 | — | — | EP | disclosed |
| WO-1987003605-A1 | OLIGOMERIZATION PROCESS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH OR (AU) | 1987-06-18 | — | — | WO | disclosed |
| US-4338291-A | Process for producing hydrogen with viologen cation radical using metal complex of macrocyclic polydentate compound as catalyst | RIKAGAKU KENKYUSHO (JP) | 1982-07-06 | — | — | US | disclosed |
| US-4104466-A | ACRYLIC POLYMER LIGANDS, ADSORPTION AND DESORPTION OF OXYGEN | Tsuchida, Eishun (JP) | 1978-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127293-A1 | LIQUID METAL COMPLEX HAVING OXYGEN-ABSORBING ABILITY | OTC, CA9, SLC39A14 | HTT 4795/4885MGAM 1118/4885GAA 2415/4885 |
| US-20230422602-A1 | CERIUM-ETHYLENEDIAMINE KETONE-TYPE AND CERIUM-SALEN-TYPE COMPLEXES AND USE THEREOF IN ORGANIC ELECTRONICS | KCNH3, KCNE1, PDHA1 | HTT 1590/4885MGAM 3943/4885GAA 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.